Oxurion clinical trials

Also known as ThromboGenics.

The registry lists 32 studies whose lead sponsor is Oxurion or one of 2 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 27, 2023.

Studies

Recruiting first, then most recently updated. Showing 32 of 32.

• A Study to Evaluate THR-149 Treatment for Diabetic Macular OedemaCompletedNCT04527107Phase 2
• A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.TerminatedNCT05063734Phase 2
• A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory MedulloblastomaCompletedNCT02748135Phase 1

  Sponsor listed in the registry: Oncurious NV

• A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDRTerminatedNCT02681809Phase 2

  Sponsor listed in the registry: ThromboGenics

• A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)CompletedNCT03669393Phase 2

  Sponsor listed in the registry: ThromboGenics

• A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)CompletedNCT03666923Phase 1

  Sponsor listed in the registry: ThromboGenics

• A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)CompletedNCT03499223Phase 2
• A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)CompletedNCT03511898Phase 1

  Sponsor listed in the registry: ThromboGenics

• A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)CompletedNCT03071068Phase 2

  Sponsor listed in the registry: ThromboGenics

• Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin StudiesCompletedNCT01287988

  Sponsor listed in the registry: ThromboGenics

• Ocriplasmin Research to Better Inform Treatment (ORBIT)CompletedNCT02079883

  Sponsor listed in the registry: ThromboGenics

• Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular HoleCompletedNCT01429441Phase 3

  Sponsor listed in the registry: ThromboGenics

• A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMACompletedNCT02193945

  Sponsor listed in the registry: ThromboGenics

• Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular AdhesionCompletedNCT00913744Phase 2

  Sponsor listed in the registry: ThromboGenics

• Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for VitrectomyCompletedNCT00986362Phase 2

  Sponsor listed in the registry: ThromboGenics

• The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)CompletedNCT01159665Phase 2

  Sponsor listed in the registry: ThromboGenics

• A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)CompletedNCT00412958Phase 2

  Sponsor listed in the registry: ThromboGenics

• Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.CompletedNCT00798317Phase 3

  Sponsor listed in the registry: ThromboGenics

• A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)CompletedNCT00435539Phase 2

  Sponsor listed in the registry: ThromboGenics

• Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.CompletedNCT00781859Phase 3

  Sponsor listed in the registry: ThromboGenics

• A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)CompletedNCT00412451Phase 2

  Sponsor listed in the registry: ThromboGenics

• Intravenous Administration of Microplasmin for Treatment of Acute Ischemic StrokeCompletedNCT00123305Phase 2

  Sponsor listed in the registry: ThromboGenics

• Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVTTerminatedNCT00428129Phase 2

  Sponsor listed in the registry: ThromboGenics

• Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery OcclusionTerminatedNCT00123266Phase 2

  Sponsor listed in the registry: ThromboGenics

• Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial OcclusionTerminatedNCT00123292Phase 2

  Sponsor listed in the registry: ThromboGenics

• Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular AdhesionCompletedNCT01055535Phase 2

  Sponsor listed in the registry: ThromboGenics

• A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male VolunteersCompletedNCT00612196Phase 1

  Sponsor listed in the registry: ThromboGenics

• Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402CompletedNCT00612417Phase 1

  Sponsor listed in the registry: ThromboGenics

• Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement SurgeryCompletedNCT00793234Phase 2

  Sponsor listed in the registry: ThromboGenics

• Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With WarfarinCompletedNCT00618579Phase 1

  Sponsor listed in the registry: ThromboGenics

• Intravitreal Microplasmin in Patients Undergoing Surgical VitrectomyCompletedNCT00123279Phase 2

  Sponsor listed in the registry: ThromboGenics

• Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement SurgeryCompletedNCT01344954Phase 2

  Sponsor listed in the registry: ThromboGenics